Payment overview · 2025
General Payments
$31,676.34
255 reported records · 35 companies
Healthcare provider profile · identity verified
Alexis Bashinski Shaefer, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · AUGUSTA, GA · NPI 1942590872
Verified facts
What the public records show
CMS Open Payments records show Alexis Bashinski Shaefer, M.D. received $31,676.34 in general payments during 2025 across 255 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 71.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Gamunex-C, Nurtec Odt, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rytary by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gamunex-C by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22,676.82 | 71.6% | 44 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $3,581.16 | 11.3% | 45 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $2,010.49 | 6.3% | 24 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $324.23 | 1.0% | 11 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $232.96 | 0.7% | 9 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $217.94 | 0.7% | 8 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $207.22 | 0.7% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $206.12 | 0.7% | 8 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $203.90 | 0.6% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $197.88 | 0.6% | 9 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$195.38 | 0.6% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $158.36 | 0.5% | 5 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $145.75 | 0.5% | 6 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $142.30 | 0.5% | 9 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $137.26 | 0.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $115.12 | 0.4% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $109.60 | 0.3% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $89.78 | 0.3% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$88.69 | 0.3% | 3 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $65.89 | 0.2% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $60.41 | 0.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.99 | 0.2% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.49 | 0.2% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $51.71 | 0.2% | 3 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $49.58 | 0.2% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.71 | 0.1% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $39.01 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $37.53 | 0.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.38 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.10 | 0.1% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $24.91 | 0.1% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $24.76 | 0.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.68 | 0.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $18.80 | 0.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.43 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,677.50 | 9 |
| Food and Beverage | $5,212.14 | 217 |
| Travel and Lodging | $5,170.45 | 27 |
| Consulting Fee | $1,525.00 | 1 |
| Education | $91.25 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $22,676.82 | 44 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $3,063.39 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $1,879.10 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $476.07 | 25 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $360.49 | 26 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $354.10 | 17 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $300.81 | 14 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $232.96 | 9 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $217.94 | 8 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $197.88 | 9 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $195.38 | 8 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $185.89 | 7 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $168.35 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $158.36 | 5 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $142.30 | 9 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $131.39 | 6 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $109.60 | 6 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $101.89 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $100.87 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $96.71 | 5 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $89.78 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $77.22 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $65.89 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $60.41 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $55.07 | 5 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $52.49 | 2 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $51.71 | 3 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $49.58 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $49.58 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $46.06 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $41.71 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $39.01 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $37.53 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $36.38 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $29.49 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| REYVOW Normalized: reyvow |
Drug | Lilly USA, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 251 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 205 | 66 |
| Gabapentin | Gabapentin | 149 | 52 |
| Levetiracetam | Levetiracetam | 126 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 28 |
| Donepezil Hcl | Donepezil Hcl | 108 | 43 |
| Lamotrigine | Lamotrigine | 89 | 16 |
| Primidone | Primidone | 84 | 27 |
| Pregabalin | Pregabalin | 78 | 36 |
| Zonisamide | Zonisamide | 75 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 19 |
| Topiramate | Topiramate | 60 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Baclofen | Baclofen | 56 | 18 |
| Rasagiline Mesylate | Rasagiline Mesylate | 48 | 12 |
| Trazodone Hcl | Trazodone Hcl | 48 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 45 | suppressed |
| Ubrelvy | Ubrogepant | 45 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 39 | 12 |
| Clonazepam | Clonazepam | 38 | 16 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 37 | suppressed |
| Amantadine | Amantadine Hcl | 35 | suppressed |
| Diazepam | Diazepam | 35 | 11 |
| Memantine Hcl | Memantine Hcl | 34 | 11 |
| Carbamazepine Er | Carbamazepine | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 28 | 11 |
| Emgality Pen | Galcanezumab-Gnlm | 28 | suppressed |
| Rytary | Carbidopa/Levodopa | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Entacapone | Entacapone | 22 | suppressed |
| Prednisone | Prednisone | 22 | 11 |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Briviact | Brivaracetam | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 15 | suppressed |
| Lamotrigine Er | Lamotrigine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 13 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Zoloft | Sertraline Hcl | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 12 | suppressed |
| Keppra Xr | Levetiracetam | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Betaseron | Interferon Beta-1b | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $31,676.34 · 255 records | Takeda Pharmaceuticals U.S.A., Inc. | AJOVY, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CREXONT, EMGALITY, EPIDIOLEX, Gamunex-C, Gocovri, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, QUTENZA, Qelbree, REXULTI, REYVOW, Radicava, Rystiggo, TRUDHESA, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, WAKIX, Xeomin, ZAVZPRET, Zilbrysq | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error